CO2021015998A2 - Materiales y métodos para modular la inmunidad mediada por células t - Google Patents

Materiales y métodos para modular la inmunidad mediada por células t

Info

Publication number
CO2021015998A2
CO2021015998A2 CONC2021/0015998A CO2021015998A CO2021015998A2 CO 2021015998 A2 CO2021015998 A2 CO 2021015998A2 CO 2021015998 A CO2021015998 A CO 2021015998A CO 2021015998 A2 CO2021015998 A2 CO 2021015998A2
Authority
CO
Colombia
Prior art keywords
methods
modulating
materials
antibodies
cell mediated
Prior art date
Application number
CONC2021/0015998A
Other languages
English (en)
Inventor
Rajkumar Ganesan
Sanjaya Singh
Iqbal S Grewal
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CO2021015998A2 publication Critical patent/CO2021015998A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen anticuerpos anti-TRGV9 o fragmentos de unión al antígeno de estos. También se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y métodos para usar los anticuerpos para tratar o prevenir enfermedades, tales como el cáncer.
CONC2021/0015998A 2019-05-08 2021-11-26 Materiales y métodos para modular la inmunidad mediada por células t CO2021015998A2 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962844966P 2019-05-08 2019-05-08
US201962844995P 2019-05-08 2019-05-08
US201962844959P 2019-05-08 2019-05-08
US201962844970P 2019-05-08 2019-05-08
US201962844976P 2019-05-08 2019-05-08
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity

Publications (1)

Publication Number Publication Date
CO2021015998A2 true CO2021015998A2 (es) 2021-12-10

Family

ID=73051172

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0015998A CO2021015998A2 (es) 2019-05-08 2021-11-26 Materiales y métodos para modular la inmunidad mediada por células t

Country Status (21)

Country Link
US (2) US11667712B2 (es)
EP (1) EP3965818A4 (es)
JP (1) JP2022533538A (es)
KR (1) KR20220017892A (es)
CN (1) CN113966231A (es)
AU (1) AU2020267504A1 (es)
BR (1) BR112021022089A2 (es)
CA (1) CA3139508A1 (es)
CL (1) CL2021002905A1 (es)
CO (1) CO2021015998A2 (es)
CR (1) CR20210548A (es)
DO (1) DOP2021000229A (es)
EC (1) ECSP21087921A (es)
IL (1) IL287817A (es)
JO (1) JOP20210297A1 (es)
MA (1) MA55903A (es)
MX (1) MX2021013532A (es)
PE (1) PE20220763A1 (es)
SG (1) SG11202112021QA (es)
TW (1) TW202108618A (es)
WO (1) WO2020227457A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
EP4298125A1 (en) 2021-02-26 2024-01-03 LAVA Therapeutics N.V. Antibodies that bind cd123 and gamma-delta t cell receptors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2467738A1 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2347038A4 (en) 2008-10-14 2013-06-12 Janssen Biotech Inc METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MX2012002766A (es) 2009-09-03 2012-04-02 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
MX353144B (es) 2010-04-20 2017-12-20 Genmab As Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
BR112013002831A2 (pt) 2010-08-05 2016-11-01 Anaptysbio Inc anticorpos direcionados contra a il-17
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
JP6339015B2 (ja) * 2011-08-23 2018-06-06 ロシュ グリクアート アーゲー 二重特異性t細胞活性化抗原結合分子
PT2773671T (pt) 2011-11-04 2021-12-14 Zymeworks Inc Geração de anticorpo heterodimérico estável com mutações no domínio fc
US9718893B2 (en) * 2011-12-19 2017-08-01 Synimmune Gmbh Bispecific antibody molecule
EP3060059A4 (en) * 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
JP6617138B2 (ja) * 2014-04-10 2019-12-11 ラヴァ・セラピューティクス・ベー・フェー ヒトVγ9Vδ2 T細胞受容体と結合する免疫グロブリン
US10144779B2 (en) 2015-05-29 2018-12-04 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
AU2017388346A1 (en) 2016-12-26 2019-07-11 Kagoshima University Antibody capable of binding to myelin oligodendrocyte glycoprotein
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
EP3743081A4 (en) 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
WO2021173896A1 (en) 2020-02-27 2021-09-02 Janssen Biotech, Inc. Materials and methods for modulating an immune response
US20210284731A1 (en) 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
CA3199767A1 (en) 2020-10-28 2022-05-05 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity

Also Published As

Publication number Publication date
JOP20210297A1 (ar) 2023-01-30
US20240150464A1 (en) 2024-05-09
CR20210548A (es) 2022-02-11
KR20220017892A (ko) 2022-02-14
BR112021022089A2 (pt) 2022-02-08
MX2021013532A (es) 2022-02-11
CA3139508A1 (en) 2020-11-12
SG11202112021QA (en) 2021-11-29
CL2021002905A1 (es) 2022-06-17
CN113966231A (zh) 2022-01-21
WO2020227457A1 (en) 2020-11-12
DOP2021000229A (es) 2022-07-31
JP2022533538A (ja) 2022-07-25
AU2020267504A1 (en) 2021-12-02
US20210032338A1 (en) 2021-02-04
TW202108618A (zh) 2021-03-01
ECSP21087921A (es) 2022-01-31
EP3965818A1 (en) 2022-03-16
EP3965818A4 (en) 2023-05-31
IL287817A (en) 2022-01-01
MA55903A (fr) 2022-03-16
US11667712B2 (en) 2023-06-06
PE20220763A1 (es) 2022-05-16

Similar Documents

Publication Publication Date Title
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
CL2019002566A1 (es) Anticuerpos anti-phf-tau y usos de estos.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
BR112021020629A2 (pt) Compostos bicíclicos
CO2018012374A2 (es) Moléculas de anticuerpo para el tratamiento del cáncer
DOP2022000082A (es) Heterociclos bicíclicos como inhibidores de fgfr
CO2021015998A2 (es) Materiales y métodos para modular la inmunidad mediada por células t
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
UY39416A (es) Moléculas de direccionamiento inmunes multiespecíficas y usos de estas
CO2018010827A2 (es) Anticuerpos anti-factor bb del complemento y usos de estos
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
CL2022002766A1 (es) Anticuerpos anti-phf-pau y sus usos.
EA202190807A1 (ru) Антитела к синуклеину
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
UY39699A (es) Anticuerpos anti-tau y usos de estos
UY39415A (es) Métodos y composiciones para modular la inmunidad mediada por cadenas beta
EA202092122A1 (ru) Антитела против tip-1 и их применения
UY39127A (es) Materiales y métodos para modular la inmunidad mediada por cadena delta
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками
AR115424A1 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33 / anti-cd3 y usos de estos
EA202092121A1 (ru) Антитела против cd73 и их применения
CO2022003324A2 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
ECSP22020678A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares